Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 3/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30454415 | 0.85 | LPL (0.41) | GPR3LIPELPLLIPGCXCR2 | |
| SCHEMBL25357432 | 0.85 | LPL (0.41) | GPR3LIPELPLLIPGCXCR2 | |
| SCHEMBL16373781 | 0.84 | LIPE (0.39) | LIPELPLLIPGCXCR2EGFR | |
| SCHEMBL22715527 | 0.84 | HRH4 (0.34) | LIPELPLLIPGCXCR2EGFR | |
| SCHEMBL18605166 | 0.84 | LIPE (0.33) | LIPELPLLIPGCXCR2EGFR | |
| SCHEMBL4785145 | 0.82 | SNCA (0.38) | LIPECXCR2EGFR | |
| SCHEMBL15454943 | 0.81 | ACHE (0.47) | ACHECSF1REGFR | |
| SCHEMBL31721190 | 0.79 | TDP1 (0.38) | — | |
| SCHEMBL18605095 | 0.76 | ALDH1A1 (0.49) | LIPECXCR2 | |
| SCHEMBL21452293 | 0.76 | LPL (0.41) | LPLLIPGCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183241-B1 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LTD (GB) | 2012-12-19 | — | — | EP | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008135826-A2 | 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048306-A1 | PYRIDINE DERIVATIVES | SDHA, P2RX4, P2RX3 | GPR3 1143/4885LIPE 4674/4885LPL 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.